Marshall Wace’s Recursion Pharmaceuticals RXRX Stock Holding History

Marshall Wace’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.3M	Buy	4,714,577 +1,837,649	+64%	+$6.12M	0.01%	787
2026 Q1	$8.83M	Buy	2,876,928 +2,650,319	+1,170%	+$10.2M	0.01%	1036
2025 Q4	$927K	Buy	226,609 +148,350	+190%	+$735K	﹤0.01%	1970
2025 Q3	$382K	Sell	78,259 -8,053	-9%	-$42.3K	﹤0.01%	2334
2025 Q2	$437K	Sell	86,312 -247,300	-74%	-$1.21M	﹤0.01%	2194
2025 Q1	$1.76M	Buy	+333,612	New	+$2.43M	﹤0.01%	1520
2024 Q2	–	Sell	-391,518	Closed	-$3.9M	–	2902
2024 Q1	$3.9M	Buy	+391,518	New	+$4.36M	0.01%	1098
2023 Q2	–	Sell	-514,137	Closed	-$3.43M	–	2915
2023 Q1	$3.43M	Buy	+514,137	New	+$4.08M	0.01%	1178
2022 Q3	–	Sell	-106,786	Closed	-$869K	–	3737
2022 Q2	$869K	Buy	+106,786	New	+$715K	﹤0.01%	2526

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Marshall Wace's RXRX Position: Q2 2026 in Review

Marshall Wace increased its Recursion Pharmaceuticals (RXRX) stake by 64% in Q2 2026, buying an estimated $6.12M and bringing the position to 4,714,577 shares worth $17.3M. The position accounts for 0.01% of the portfolio, ranked #787.

Marshall Wace first reported a position in RXRX in Q2 2022 and has held it in 9 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Marshall Wace held 4,714,577 shares of Recursion Pharmaceuticals worth $17.3M as of Q2 2026.
Marshall Wace bought 1,837,649 Recursion Pharmaceuticals shares in Q2 2026, an estimated $6.12M.
Recursion Pharmaceuticals made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #787 holding.
Marshall Wace first reported a position in Recursion Pharmaceuticals in Q2 2022 and has held it in 9 quarters since.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.